ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Candel Therapeutics Inc

Candel Therapeutics Inc (CADL)

6.605
-0.06
(-0.90%)
At close: January 21 4:00PM
6.65
0.045
( 0.68% )
After Hours: 7:05PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
6.65
Bid
6.60
Ask
6.88
Volume
1,002,837
6.45 Day's Range 6.91
1.16 52 Week Range 14.60
Market Cap
Previous Close
6.665
Open
6.82
Last Trade Time
19:05:43
Financial Volume
$ 6,684,612
VWAP
6.6657
Average Volume (3m)
4,115,440
Shares Outstanding
32,475,537
Dividend Yield
-
PE Ratio
-5.66
Earnings Per Share (EPS)
-1.17
Revenue
-
Net Profit
-37.94M

About Candel Therapeutics Inc

Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel Therapeutics Inc is a late clinical stage biopharmaceutical company. It is focused on helping patients fight cancer with oncolytic viral immunotherapies.

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
-
Candel Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CADL. The last closing price for Candel Therapeutics was $6.67. Over the last year, Candel Therapeutics shares have traded in a share price range of $ 1.16 to $ 14.60.

Candel Therapeutics currently has 32,475,537 shares outstanding. The market capitalization of Candel Therapeutics is $216.45 million. Candel Therapeutics has a price to earnings ratio (PE ratio) of -5.66.

CADL Latest News

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-1.16-14.85275288097.818.086.621138227.63662599CS
4-1.86-21.85663924798.519.86836.617041978.33432251CS
121.2222.4677716395.4314.63.78541154407.8172565CS
260.6410.64891846926.0114.63.78519713117.70763382CS
525.38423.6220472441.2714.61.1624907757.13100111CS
1560.46.46.2514.60.668918066.72423146CS
260-1.35-16.875814.780.667795336.76007535CS

CADL - Frequently Asked Questions (FAQ)

What is the current Candel Therapeutics share price?
The current share price of Candel Therapeutics is $ 6.65
How many Candel Therapeutics shares are in issue?
Candel Therapeutics has 32,475,537 shares in issue
What is the market cap of Candel Therapeutics?
The market capitalisation of Candel Therapeutics is USD 216.45M
What is the 1 year trading range for Candel Therapeutics share price?
Candel Therapeutics has traded in the range of $ 1.16 to $ 14.60 during the past year
What is the PE ratio of Candel Therapeutics?
The price to earnings ratio of Candel Therapeutics is -5.66
What is the reporting currency for Candel Therapeutics?
Candel Therapeutics reports financial results in USD
What is the latest annual profit for Candel Therapeutics?
The latest annual profit of Candel Therapeutics is USD -37.94M
What is the registered address of Candel Therapeutics?
The registered address for Candel Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Candel Therapeutics website address?
The website address for Candel Therapeutics is www.candeltx.com
Which industry sector does Candel Therapeutics operate in?
Candel Therapeutics operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NEHCNew Era Helium Inc
$ 3.99
(45.62%)
2.97M
CDIOCardio Diagnostics Holdings Inc
$ 0.84
(38.16%)
9.9M
TOIIWOncology Institute Inc
$ 0.022
(29.41%)
6.13k
NFXLDirexion Daily NFLX Bull 2X Shares
$ 45.00
(27.59%)
420.65k
MGXMetagenomi Inc
$ 3.3694
(23.88%)
5.48M
AGYSAgilysys Inc
$ 99.77
(-20.75%)
36.17k
LSTALisata Therapeutics Inc
$ 3.17
(-18.72%)
51.8k
INMInMed Pharmaceuticals Inc
$ 4.15
(-17.82%)
174.08k
XLOXilio Therapeutics Inc
$ 1.0498
(-17.34%)
330.21k
HUBCWHub Cyber Security Ltd
$ 0.04
(-16.14%)
20.17k
ACONAclarion Inc
$ 0.0454
(6.82%)
20.65M
GCTKGlucoTrack Inc
$ 0.1201
(-3.92%)
10.07M
CDIOCardio Diagnostics Holdings Inc
$ 0.84
(38.16%)
9.9M
RIMEAlgorhythm Holdings Inc
$ 0.0368
(6.36%)
9.53M
NVDANVIDIA Corporation
$ 142.8001
(1.40%)
8.73M

CADL Discussion

View Posts
Dell_Griffith Dell_Griffith 23 hours ago
As I said, I should have known...

Thanks again.
πŸ‘οΈ0
dia76ca dia76ca 2 days ago
BP = Big Pharma
👍️ 1
Dell_Griffith Dell_Griffith 2 days ago
Sorry for my ignorance, but what is "BP"? Sorry if it's mentioned elsewhere on this board and I missed it.

Agreed, late 2026 is not a fun timeline, but hoping they come out with additional info before then.

And although they all have their "small window" to sell to earn their compensation, never pleasant to see that as well.
πŸ‘οΈ0
rosemountbomber rosemountbomber 5 days ago
Little disappointed with the very late 2026 submission date.  Heard someone say it was because they had to nail down the manufacturing first.  Somehow they would be better off selling to BP and be done with it.  Although very happy with prostate results, just getting a little worried about the 2 readouts this qtr as pancreatic is a bitch. 
👍️ 1
georgie18 georgie18 5 days ago
CADL...$7.81...🥳...50/100 Ready to Cross the 200... https://schrts.co/nPxatndN

On track to report updated overall survival data for CAN-2409 from phase 2a clinical trials in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025
Preparations for Biologics License Application (BLA) for CAN-2409 in prostate cancer underway, with submission expected in Q4 2026
The Company intends to present phase 3 clinical trial data from CAN-2409 in prostate cancer at upcoming scientific conferences
On track to report overall survival data in patients with recurrent high-grade glioma (rHGG) from ongoing phase 1b trial evaluating multiple doses of CAN-3110, expected in Q4 2025
The Company expects that its cash and cash equivalents of approximately $103M (unaudited) as of December 31, 2024, will be sufficient to fund its current operating plan into Q1 of 2027
NEEDHAM, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today highlighted recent successes across the Company's viral immunotherapy portfolio and provided an update on the Company’s cash position and upcoming 2025 milestones.
πŸ‘οΈ0
rosemountbomber rosemountbomber 6 days ago
Stock rallied late and put in a hammer on the charts. More than average volume. Hopefully that is the tone going forward.
πŸ‘οΈ0
rosemountbomber rosemountbomber 6 days ago
Hope we get some good news in 1st qtr on the two other readouts because as we may need it to stem the selling.  This is what sellers may be seizing upon:  Fast track, orphan status, etc., yet now they are saying FDA filing not until 4th qtr 2026.  Come on. Yeah waiting to line up publication of study and manufacturing.  
πŸ‘οΈ0
rosemountbomber rosemountbomber 6 days ago
Company had some SEC filings today which apparently are explaining the dilution (which was announced in Dec) and I guess that is behind the drop today 
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 weeks ago
You are most welcome.
👍️ 1
Dell_Griffith Dell_Griffith 4 weeks ago
Thanks for posting this interview. Great info. Thank you.
πŸ‘οΈ0
Dell_Griffith Dell_Griffith 4 weeks ago
Thanks for posting this interview. Great info. Thank you.
πŸ‘οΈ0
Dell_Griffith Dell_Griffith 4 weeks ago
Great insights, thanks.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 4 weeks ago
On Feuerstein: He is an influencer - he needs content so he will say something about everything that is up or down.

On Tak, check out his history at Flagship on top of his time at GSK. Im sure if they put the right amount of $$ on the table he will "switch his mind".

Remember prostate is notoriously
immunologically cold but CAN 2409 still worked...
So I believe it wil be even more effective in NSCLC and panc.
👍️ 1
rosemountbomber rosemountbomber 4 weeks ago
No question PBM is a heavyweight in small biotech investing. And of course as you mention Paul Manning who leads them is on the board at Candel and just sank a bunch of money into buying shares personally it seems.

For those who are not that familiar with CADL, this short talk with CEO Tak is a good primer:



If I had to pick a couple of things that were the least positive in that talk, I would say these would be it:
1) Around 5:40 mark, Tak talking about some clinical trial results are coming in the next qtr and "if several of these are positive".... - tough enough to have one study meet endpoints, so hoping for several positive results adds just a bit more anxiety to this. But hopefully past data dictates hope might be justified.
2) Although Tak mentions the path forward will probably involved BP in the form of partnerships, he seems to leave the U.S. market for CADL alone and talks about turning the company into a small Pharma. Although he worked for GSK and recognizes how BP has a much greater ability to drive sales, his mentioning of keeping the US for himself sends up red flags for me about GIA. I have seen that happen to so many small bios. Egos eventually doom the path forward.

Will be watching this closely.
👍️ 2
Monksdream Monksdream 1 month ago
CADL under $9
πŸ‘οΈ0
Dell_Griffith Dell_Griffith 1 month ago
I think the key here is that PBM Capital is involved. I’m sure you checked out their investing history, but it’s impressive. Further, it looks like Paul Manning is directly involved.

As for Feuerstein, even broken clocks are right twice a day.
πŸ‘οΈ0
rosemountbomber rosemountbomber 1 month ago
I notice that an old nemesis (in another stock years ago) Adam Feuerstein seems to be mostly bashing CADL. Not sure what his deal is. He has attacked CADL in relation to a lung cancer trial since it was not placebo controlled. But not really sure what his problem is here with prostate cancer.

I will say that there seems to be one point that he may have and that I find confusing myself. If anyone can better explain this one top line bullet point in the press release I would appreciate it:

Operator
05/09/2024 at 06:17 PM
This is a common misconception that this strip is common area, but it is actually a part of your lot and needs to be maintained the same as your lawn. No worries though, we are only recently sending out letters/citations about landscape maintenance so you do not need to worry about being fined in the meantime. For reference, it takes close to two months for us to issue fines following the initial citation, so you have plenty of time to make arrangements to accommodate this.

"14.5% relative improvement in DFS observed at 54 months for the CAN-2409 treatment arm compared to the placebo control arm"

I am not sure exactly what they are saying. I know AF also questions why specifically the 54 months. TIA
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
9.42
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
great
πŸ‘οΈ0
rosemountbomber rosemountbomber 1 month ago
Triple avg volume so far today with an hour left.  
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
NICE rebound this morning how long will it last
👍️ 1
rosemountbomber rosemountbomber 1 month ago
Big insider purchase 2 days ago:

https://www.secform4.com/filings/1841387/0000950170-24-137889.htm
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
why not the ATM
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
Not very TAK ful
couldve been done a lot better I believe
now driftwood until the next readout.... Will be another opportunity
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
CADL: Hopefully, they get a CURE for all that bad PROSTATE stuff!!! (Had 1/3rd mine removed at the VA Hospital in Palo Alto few years back; NO joking!! And yet STILL must get up circa 4-times every night to PISS --- not fun. And even Orion's 'Mr. Monk' posted, if I'm not mistaken, that he HAS Prostate Cancer itself.)
πŸ‘οΈ0
tw0122 tw0122 1 month ago
$7 + 4% 3.3 million offerings at 5.99 sunk it down 50%. Need cash for last part of trial prostate...another $18 million 

πŸ‘οΈ0
Dell_Griffith Dell_Griffith 1 month ago
Not ideal, that's for sure, but development stage, they don't have much of a choice. Did you check out the CMO? He was with Chimerix when it soared and was a solid Company. Left well before they fell apart.

The execs at Candel are solid. Whether they can get it done, is another story, of course.

Can't see a dip below 6, but seems to make sense to average down. Good luck, if you're in it.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
thats not how you build trust Peter!
👍️ 1
PonkenPlonken PonkenPlonken 1 month ago
yikes
πŸ‘οΈ0
Woodpecker3 Woodpecker3 1 month ago
$CADL Doubled shares overnight with offering now has 60 million shares increased from 30 million shares. Expect this dilution will take it to below $4 level it was at prior to run up this week. Remember: $CADL has no revenues, at risk that it will never have a product and is losing close to 40 million $ per year. FDA trials take years and this will be a zombie stock. Watch for $3 to 4$ price level due to dilution.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
7.5s..
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
The stock isn’t going to zero
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
My problem is that I dont have a feeling for when that is most relevant.
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
Short positions do represent potential buying power
👍️ 1
PonkenPlonken PonkenPlonken 1 month ago
I always interpet them as to-be-buyers too.
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
It happens with these biomed stocks after a press release
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
And a lot of shares still sold short
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
Apparently professional asset managers did take a liking to this stock
👍️ 1
Invest-in-America Invest-in-America 1 month ago
CADL: No Sir!!! I simply WISH we had some legitimate "SCIENCE" somewhere on this Planet --- primarily in HEALTH CARE, MEDICINE, LIFE EXTENSION, GENOMICS, etc.
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
You are one of these anti-science people?
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
go go
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
CADL: If you SCORED some nice bucks behind this fluff news, well, CONGRATS to ya, Dude!!! That's ALL you can do with this "Health Science" crap!!! NEVER hold this MEDICAL junk long!!! Not even during ONE day of their bogus PR's. The simple fact that every hospital on this moronic Planet has a GERIATRICS DEPARTMENT is dispositive PROOF that this Planet has NO FUCKING KNOWLEDGE WHATSOEVER ABOUT ANY ASPECT OF HUMAN PHYSIOLOGY!!!!! Lastly, there's another Department in every hospital on this mindless Planet --- for which, however, said hospitals do not even display SIGNAGE --- but it is called, THE CEMETERY DEPARTMENT!!! And we ALL eventually go there!!! Even every one of the stupid DOCTORS, NURSES, & TECHNICIANS who are employed in those "Hospitals"!!! (Have ya finally learned the TRUTH about "Medical Science" today, fella??? And from a fellow iHuber!!!)
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
will be used in all cancers with nestin overexpression eventually
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
See who commented on the stock before today. I even commented last night. I think its fair to say i had conviction.
You guys are late to the party then tell me how bad their science is after the fact ... with the stock up 180% in the morning?
GL with that
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
--------------------------------
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
CADL: I know this stuff, you don't.

"Immunotherapy drugs like Candel's teach the immune system to find and destroy cancer cells. The drug helped 75.2% of patients with intermediate-to-high risk localized prostate cancer live for 54 months without any sign of cancer. In comparison, just 65.7% of the radiation-only group met the same bar."

If you think such PETTY differences in such 'studies' is significant, you are just plain IGNORANT!! I paltry 10% difference???!!!
πŸ‘οΈ0
PonkenPlonken PonkenPlonken 1 month ago
Meet primary endpoint ph3 = fluff news
lol
What would be a PR of substance? Scientists turn lead into gold? Or breed the golden goose?
πŸ‘οΈ0
Invest-in-America Invest-in-America 1 month ago
CADL: So much for such Phase-3 Medical BULLSHIT --- mere STATISTICAL ARTIFACTS --- so-called 'history-making' (baloney) "news" about Prostate Cancer!!! (The worst "Cancer" on this reprobate Planet is the MEDICAL IGNORANCE of the "Doctors" & "Researchers" THEMSELVES!!!!)
πŸ‘οΈ0
Monksdream Monksdream 1 month ago
LOST roughly half the market cap from the session high
Will professional asset managers take a liking to it
πŸ‘οΈ0
axelvento axelvento 1 month ago
https://www.biospace.com/press-releases/candel-therapeutics-announces-can-2409-achieved-primary-endpoint-in-phase-3-prostate-cancer-trial-showing-significantly-improved-disease-free-survival
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock